Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Insulin for HIV-associated Neurocognitive Disorder
NCT03081117Phase 2Terminated
- Sponsor
- Johns Hopkins University
- Start
- Aug 2017
- Primary completion
- May 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of intranasal insulin in HIV-associated neurocognitive disorder (HAND) (2 arms), sponsored by Johns Hopkins University. Primary endpoints: Serious Adverse Event Frequency at 24 weeks and Global Deficit Score at 24 weeks. Started Aug 2017; status: terminated.
02
Drugs
intranasal insulin
03
Conditions
HIV-associated neurocognitive disorder (HAND)
Beyond the preview
Go deeper on NCT03081117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03081117.